The European Medicines Agency (EMA) has recommended to grant MediWound marketing authorization for NexoBrid™ in the European Union (EU) for removal of eschar in adult patients with deep partial- and/or full-thickness thermal burns. This approval follows EMA’s Good Manufacturing Practices (cGMP) approval for MediWound’s sterile manufacturing plant and laboratories. NexoBrid™...
Read more
Category Archives: biotechnology
Can-Fite Phase II for Liver Cancer
Can-Fite BioPharma (TASE: CFBI, OTC: CANFY), has initiated a Phase 2 study with its anti-cancer drug CF102, the second drug in its pipeline of A3 adenosine receptor ligands. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). Based on the successful conclusion of a...
Read more
Evogene to Raise $60 M
Evogene Ltd. (TASE:EVGN) has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $60 million in a public offering on the New York Stock Exchange. Evogene uses computational genomics technologies to Spritz amount have pharmacy no prescription needed contrasting over-the-counter the face http://tecletes.org/zyf/aciclovir-dosis ok which...
Read more
Bio-Chem Offers Data Loggers for Critical Parameter Monitoring
Bio-Chem Engineering is now offering the monitoring and analysis of temperature, relative humidity and other critical parameters using the most accurately-calibrated data loggers available. The software for the data loggers is FDA 21CFR part 11 compliant and meets all the standards of the biopharma industry. Uses for the data loggers...
Read more
Compugen’s $500 M Deal With Bayer
Compugen Ltd. (NASDAQ: CGEN) signed a deal worth more than $500 million with Bayer Healthcare. The collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators will give Bayer full control over further development and have...
Read more
RegeneCure Bone Aid for Dental Implant
RegeneCure has started a clinical study using the company’s proprietary AMCA Guided Bone Regeneration Dental Membrane as a bone stimulating aid for patients requiring dental implants. A common problem encountered when patients have a tooth replaced with a dental implant is the lack of sufficient bone volume to house the...
Read more
Atox Bio Stops Flesh Eating Bacteria
Atox Bio announced new data in an animal model of necrotizing soft tissue infection (NSTI), commonly known as “flesh eating bacteria” demonstrating that administration of a single dose of AB103, given several hours after infection even without any antibiotics, increased survival in animals, and reduced tissue necrosis, inflammation and bacterial...
Read more
Biotech China May 14-16: Subsidy for Israeli Companies
Israeli companies participating in Biotech China 2014 will receive up to 40% financial support from the Chinese government. Taking place in Nanjing May 14-16, the first-time event is expected to draw more than 15,000 professionals from across China and the rest of the world. “This major event promises to pave...
Read more
IP Seminar May 29 in Tel Aviv
IP experts on the life sciences industry in China and Japan are among the attendees at Intellectual Property 2013 on May 29 at the Sheraton Hotel in Tel Aviv. The eight hour seminar is designed for In House IP executives and professionals, general counsels, CFOs, CEOs and their advisers who...
Read more
Bill Gates Grants Hervana $1M for Contraceptive
Hervana has been awarded a $1 million Round 4 Grand Challenges Explorations Grant from the Bill & Melinda Gates Foundation for the development of a long-acting, non-hormonal contraceptive platform technology. It will only have to be applied once or twice a month via a vaginal suppository – as opposed to...
Read more
Sol-Gel: Successful Phase II Rosacea
Sol-Gel Technologies announced positive results for a Phase II trial in the U.S. targeting mild-to-severe rosacea using a benzoyl peroxide drug product developed by Sol-Gel. Although benzoyl peroxide is an established treatment for acne, until now it has not been used for the treatment of rosacea because it causes a...
Read more
Redhill Gets Patent for Crohn’s
RedHill Biopharma Ltd. (TASE: RDHL)reported that the United States Patent and Trademark Office has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 12/918,310 entitled “Methods and Compositions for Treating Inflammatory Bowel Disease”, directed to RedHill’s RHB-104 indicated for the treatment of Crohn’s disease. The company...
Read more
Daniel Chain Sues Pfizer for $2M
Intellect Neurosciences has filed a breach of contract suit against Pfizer Inc. for failing to make a $2 million milestone payment for rights to its Alzheimer’s disease technology. Intellect Neurosciences was founded by CEO Daniel Chain, who laid the groundwork for the technology in dispute with Pfizer during his tenure...
Read more
Steba Prostate Cancer in Phase 3
Very few Israeli technologies reach the Phase 3 clinical stage, yet a therapy for prostate cancer, invented and developed in Rehovot, has quietly worked its way to this elite club. The technology, known as Tookad-WS, was invented at the Weizmann Institute by Prof. Avigdor Scherz and Prof. Yoram Salomon. The...
Read more
New Reasons for Doing Clinical Research in the UK: Nov.7-8 in Ramat Gan
“Israeli companies that have overlooked the UK as a trial site, now can take advantage of streamlined access that is being offered locally by the UK Israel Tech Hub and in the UK by a new agency, NOCRI, the NIHR Organization for Clinical Research Infrastructure in the UK,” says Iris...
Read more
Kamada Phase II/III for Inhaled AAT
Kamada has obtained FDA approval for a Phase II/III clinical trial of AAT-IH, the inhalable version of its AAT drug for treatment of Alpha-1 antitrypsin deficiency for the treatment of congenital emphysema. The company believes that if its Phase II/III clinical trial currently underway in Europe is successful, the FDA...
Read more
Can-Fite Phase 2-3 Psoriasis Study
Can-Fite BioPharma is continuing patient enrollment in its Psoriasis Phase 2/3 clinical study with CF101. This decision follows an interim analysis of safety and efficacy data from the first 103 patients who completed 24 weeks of treatment in the trial. The positive clinical effects of the CF101-2 mg BID dose...
Read more
OrbiMed Invests $5 M in cCam
The OrbiMed Israel Fund has completed a $5 million investment in cCam. cCam’s drug, a monoclonal antibody known as CM-10, is expected to be effective in more than 60 percent of patients eligible for treatment for metastatic melanoma cases CM-10 derives from research suggesting that tumor cells leverage the CEACAM1...
Read more
Vaxil Starts Multiple Myeloma Trial
Vaxil Bio Ltd. (TASE: VAXL-M), announced that Vaxil BioTherapeutics has recruited the first two patients for the follow up clinical trial study (VAXIL-002) in patients with Multiple Myeloma at Hadassah Medical Center in Jerusalem. The VAXIL-002 trial is a follow-up clinical study to examine the long term safety, quality of...
Read more
CollPlant Wound Closure Trial Success
CollPlant has successfully completed a wound closure clinical study opening the path toward regulatory certifications required for commercialization of CollPlant’s products. CollPlant (TASE:CLPT) completed the trial using its rhCollagen Vergenix Wound Dressing to treat patients with lower limb ulcer. The objective of the study was to assess the safety and...
Read more